Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
South Africa: Measles Outbreak Update - Greater Sekhukhune District, Limpopo Province
[National Institute for Communicable Diseases] As of 27 October 2022, the number of measles outbreak cases has increased to 11 in the Greater Sekhukhune district. The last four measles cases were reported on 20 October 2022. The ages of the measles confirmed cases ranged from 9 months to 24 years, with four males and four females. Three children were fully vaccinated for measles. Six measles cases had unknown vaccination histories, and two children had not been vaccinated against measles. One measles case was hospitalised and another developed pneumoni (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - October 28, 2022 Category: African Health Source Type: news
U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Vaccine developer Vaxcyte stock soars on results of experimental pneumonia jab
The study results could put the vaccine in line to challenge those from Pfizer and Merck. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 24, 2022 Category: Biotechnology Authors: Ron Leuty Source Type: news
ACIP Backs Recs for New Pneumococcal Vax in Previously Immunized Adults
(MedPage Today) -- The CDC's vaccine advisors updated their recommendations to clarify when to administer the 20-valent conjugate pneumococcal vaccine (PCV20; Prevnar 20) in adults who previously received the 13-valent conjugate vaccine (PCV13... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 23, 2022 Category: American Health Source Type: news
Doc Sues Over Vax Mandate; $2.6M for Missed Pneumonia Dx; Fired PA Fires Back
(MedPage Today) -- UCLA anesthesiologist Christopher Rake, MD, sued the Regents of the University of California over being fired for refusing to get vaccinated against COVID-19. He was terminated on March 1 after being placed on administrative... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 20, 2022 Category: American Health Source Type: news
St. Louis vaccine startup snags $3.6M. It expects more funding is on the way.
Omniose, a St. Louis startup focused on developing vaccines to prevent bacterial infections, has snagged $3.6 million in federal funding to advance one of its vaccine candidates.
A $3.6 million grant from the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health (NIH) will be used by Omniose for research and development on a vaccine for Klebsiella pneumoniae, a bacteria that can cause an array of infections.
For Omniose, the newly awarded grant continues … (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 18, 2022 Category: Biotechnology Authors: Nathan Rubbelke Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Group salesup 2%[1] at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye diseases)US approval...
Source: Roche Investor Update - October 18, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Basel, 18 October 2022Group salesup 2%1 at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye ...
Source: Roche Media News - October 18, 2022 Category: Pharmaceuticals Source Type: news
What Happens If I Get COVID-19 and the Flu at the Same Time?
So far, COVID-19 has come with one small silver lining for health: cases of influenza have dropped dramatically. During the first flu season during the pandemic, lockdowns kept people indoors and away from one another, limiting the virus’ ability to spread. And once people began mingling more during the next flu seasons, widespread use of masks blocked influenza’s chances of infecting large numbers of people.
But that could change this flu season, as mask mandates have disappeared and more people are interacting in close quarters in school, workplaces, sports events, public transport, and more. Health experts a...
Source: TIME: Health - October 11, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Media report claiming shortage of pneumococcal vaccines 'ill-informed', says Union health ministry
The report, which quoted health officials including Maharashtra's State Immunisation Officer, stated that a tendering delay has led to the disruption in pneumococcal vaccination schedules of tens of thousands of children across the country for over a month. "The news report is ill-informed and provides erroneous information," the ministry said in a statement. (Source: The Economic Times)
Source: The Economic Times - October 8, 2022 Category: Consumer Health News Source Type: news
Statistics published for all routine childhood vaccinations in England in 2021-22
Report includes data on 14 measures of vaccination coverage. At a national level, coverage has decreased for 13 of these. The only vaccination where coverage has increased is Pneumococcal Disease primary, but this is comparison with 2019/20 figures, as 2020-21 data not available. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 30, 2022 Category: Consumer Health News Source Type: news
CDC: Advisory Committee on Immunization Practices (ACIP)
The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) is hosting a virtual meeting on October 19-20, 2022. The agenda will include discussions on influenza vaccines, pneumococcal vaccine, meningococcal vaccines, respiratory syncytial virus vaccine, rotavirus vaccine, dengue vaccines, adult immunization schedule, child/adolescent immunization schedule, COVID-19 vaccines, and Chikungunya vaccine. Includes information on how to submit public comments or request permission to make a public comment during the meeting. Registration is not required, and the meeting is open to the...
Source: Federal Register updates via the Rural Assistance Center - September 16, 2022 Category: Rural Health Source Type: news
ACIP Recommends PCV15 for Children Younger Than 19 Years
THURSDAY, Sept. 15, 2022 -- The 15-valent pneumococcal conjugate vaccine (PCV15) can be used for children aged younger than 19 years, according to recommendations issued by the Advisory Committee on Immunization Practices and published in the Sept.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 15, 2022 Category: Pharmaceuticals Source Type: news
Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022
This report describes the 2022 recommendation from the Advisory Committee On Immunization Practices on use of the 15-Valent Pneumococcal Conjugate Vaccine among children. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - September 15, 2022 Category: American Health Tags: Adolescent Health Advisory Committee on Immunization Practices (ACIP) Children's Health MMWR Morbidity & Mortality Weekly Report Vaccination Vaccines Pneumococcal Disease Source Type: news
